NLRC5/MHC class I transactivator is a target for immune evasion in cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 21, 2016, Pages 5999-6004

  Yoshihama, Sayuri ^a,b   Roszik, Jason ^c   Downs, Isaac ^a   Meissner, Torsten B ^d   Vijayan, Saptha ^a   Chapuy, Bjoern ^d   Sidiq, Tabasum ^a   Shipp, Margaret A ^d   Lizee, Gregory A ^c   Kobayashi, Koichi S ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b CHIBA UNIVERSITY   (Japan)

^c UNIVERSITY OF TEXAS   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cancer; CITA; Immune evasion; Mhc class I; NLRC5

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MHC CLASS 1 TRANSACTIVATOR; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; CYSTEINE PROTEINASE; HLA ANTIGEN CLASS 1; LMP-2 PROTEIN; LMP7 PROTEIN; NLRC5 PROTEIN, HUMAN; PROTEASOME; SIGNAL PEPTIDE; TAP1 PROTEIN, HUMAN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TUMOR MARKER; TUMOR PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; COPY NUMBER VARIATION; CYTOTOXIC T LYMPHOCYTE; EPIGENETICS; GENE; GENE EXPRESSION; HUMAN; IMMUNE EVASION; IMMUNOSURVEILLANCE; LMP2 GENE; METHYLATION; NLRC5 GENE; PRIORITY JOURNAL; PROMOTER REGION; SOMATIC MUTATION; TAP1 GENE; TRANSACTIVATION; TUMOR IMMUNITY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MALE; MORTALITY; NEOPLASM; PATHOLOGY; TRANSCRIPTION INITIATION; TUMOR ESCAPE;

ANTIGEN PEPTIDE TRANSPORTER-1; ANTIGEN PRESENTATION; BETA 2-MICROGLOBULIN; BIOMARKERS, TUMOR; CD8-POSITIVE T-LYMPHOCYTES; CYSTEINE ENDOPEPTIDASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NEOPLASM PROTEINS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION; TUMOR ESCAPE;

EID: 84969790506     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1602069113     Document Type: Article

References (43)

1. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331(6024):1565-1570.
2. Mittal D, Gubin MM, Schreiber RD, Smyth MJ (2014) New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 27:16-25.
3. Campoli M, Ferrone S (2008) HLA antigen changes in malignant cells: Epigenetic mechanisms and biologic significance. Oncogene 27(45):5869-5885.
4. Lampen MH, van Hall T (2011) Strategies to counteract MHC-I defects in tumors. Curr Opin Immunol 23(2):293-298.
5. Vermeulen CF, et al. (2005) Frequent HLA class I loss is an early event in cervical carcinogenesis. Hum Immunol 66(11):1167-1173.
6. Djajadiningrat RS, et al. (2015) Classic and nonclassic HLA class I expression in penile cancer and relation to HPV status and clinical outcome. J Urol 193(4):1245-1251.
7. Inoue M, et al. (2012) Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. OncoImmunology 1(7):1104-1110.
8. Hanagiri T, et al. (2013) Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer. Anticancer Res 33(5):2123-2128.
9. Qifeng S, Bo C, Xingtao J, Chuanliang P, Xiaogang Z (2011) Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics. J Thorac Cardiovasc Surg 141(3):808-814.
10. Garrido F, Cabrera T, Aptsiauri N (2010) "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy. IntJCancer127(2):249-256.
11. Meissner TB, Li A, Kobayashi KS (2012) NLRC5: A newly discovered MHC class I transactivator (CITA). Microbes Infect 14(6):477-484.
12. Kobayashi KS, van den Elsen PJ (2012) NLRC5: A key regulator of MHC class I-dependent immune responses. Nat Rev Immunol 12(12):813-820.
13. Kuenzel S, et al. (2010) The nucleotide-binding oligomerization domain-like receptor NLRC5 is involved in IFN-dependent antiviral immune responses. J Immunol 184(4): 1990-2000.
14. Meissner TB, et al. (2010) NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc Natl Acad Sci USA 107(31):13794-13799.
15. Meissner TB, Li A, Liu YJ, Gagnon E, Kobayashi KS (2012) The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity. Biochem Biophys Res Commun 418(4):786-791.
16. Meissner TB, et al. (2012) NLRC5 cooperates with the RFX transcription factor complex to induce MHC class I gene expression. J Immunol 188(10):4951-4958.
17. Ludigs K, et al. (2015) NLRC5 exclusively transactivates MHC class I and related genes through a distinctive SXY module. PLoS Genet 11(3):e1005088.
18. Staehli F, et al. (2012) NLRC5 deficiency selectively impairs MHC class I-dependent lymphocyte killing by cytotoxic T cells. J Immunol 188(8):3820-3828.
19. Biswas A, Meissner TB, Kawai T, Kobayashi KS (2012) Cutting edge: Impaired MHC class I expression in mice deficient for Nlrc5/class I transactivator. J Immunol 189(2): 516-520.
20. Tong Y, et al. (2012) Enhanced TLR-induced NF-κB signaling and type I interferon responses in NLRC5 deficient mice. Cell Res 22(5):822-835.
21. Yao Y, et al. (2012) NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens. Cell Res 22(5):836-847.
22. Robbins GR, et al. (2012) Regulation of class I major histocompatibility complex (MHC) by nucleotide-binding domain, leucine-rich repeat-containing (NLR) proteins. J Biol Chem 287(29):24294-24303.
23. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160(1-2): 48-61.
24. Terzic J, Grivennikov S, Karin E, Karin M (2010) Inflammation and colon cancer. Gastroenterology 138(6):2101-2114.e5.
25. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557-2576.
26. Esteller M (2006) Epigenetics provides a new generation of oncogenes and tumoursuppressor genes. Br J Cancer 94(2):179-183.
27. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3(6):415-428.
28. Albertson DG, Collins C, McCormick F, Gray JW (2003) Chromosome aberrations in solid tumors. Nat Genet 34(4):369-376.
29. Stranger BE, et al. (2007) Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315(5813):848-853.
30. Stratton MR (2011) Exploring the genomes of cancer cells: Progress and promise. Science 331(6024):1553-1558.
31. Fan Z, et al. (2014) Dexamethasone alleviates tumor-associated brain damage and angiogenesis. PLoS One 9(4):e93264.
32. Dubois LG, et al. (2014) Gliomas and the vascular fragility of the blood brain barrier. Front Cell Neurosci 8:418.
33. Dietrich J, Rao K, Pastorino S, Kesari S (2011) Corticosteroids in brain cancer patients: Benefits and pitfalls. Expert Rev Clin Pharmacol 4(2):233-242.
34. Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348(6230):56-61.
35. Pollack BP, Sapkota B, Cartee TV (2011) Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin Cancer Res 17(13): 4400-4413.
36. Sapkota B, Hill CE, Pollack BP (2013) Vemurafenib enhances MHC induction in BRAF (V600E) homozygous melanoma cells. OncoImmunology 2(1):e22890.
37. Li B, Ruotti V, Stewart RM, Thomson JA, Dewey CN (2010) RNA-Seq gene expression estimation with read mapping uncertainty. Bioinformatics 26(4):493-500.
38. Sproul D, et al. (2011) Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. Proc Natl Acad Sci USA 108(11):4364-4369.
39. Mermel CH, et al. (2011) GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 12(4):R41.
40. Cerami E, et al. (2012) The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401-404.
41. Forbes SA, et al. (2015) COSMIC: Exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 43(Database issue):D805-D811.
42. Gobin SJ, Peijnenburg A, Keijsers V, van den Elsen PJ (1997) Site alpha is crucial for two routes of IFN gamma-induced MHC class I transactivation: The ISRE-mediated route and a novel pathway involving CIITA. Immunity 6(5):601-611.
43. Liu H, Naismith JH (2008) An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol. BMC Biotechnol 8:91.